An evaluation of the Automicrobic System (AMS) for Urines (Vitek Systems, Inc.) 
The primary purpose of our evaluation was to determine the validity of the promotional claims made by the manufacturer. Secondarily, we desired to determine the feasibility of incorporating the AMS into our clinical microbiology laboratory (CML). During the course of the evaluation, several items of interest to clinical microbiologists became apparent, and we feel they are worthy of reporting.
MATERIALS AND METHODS Specimens. Initially all urine specimens received in the CML for routine culture were inoculated into AMS identification cards. After 500 true negative results were obtained, all urine specimens were visually screened grossly against a lighted background and all clear specimens were discarded to decrease the number of negative responses. Since Serratia sp. and Staphylococcus sp. (particularly Staphylococcus aureus) occur at a low frequency in urine specimens in our laboratory, all isolates of these two organisms from other types of specimens were saved and used for seeded urine specimens. Some Serratia sp. cultures were obtained from outside laboratories. Fresh isolates of other organisms, which the AMS is not designed to identify, were also obtained from the CML and utilized for seeded specimens.
Seeded specimens were prepared by making a suspension of the organism in 5 ml of 0.5% sodium chloride, adjusting to an 0. 5 McFarland turbidimetric standard, transferring 0.2 ml from the suspension to 1.8 ml of 0.5% saline, and then transferring 0.2 ml of this suspension to 1.8 ml of sterile pooled urine (see AMS Operators Manual, Vitek Systems, Inc.).
Equipment. The AMS consists of five modules: the diluent dispenser, filling module, reader-incubator module, computer/control module, and cathode ray tube data terminal with printer. These five units occupy 0.73 m2 of space and exhibit a total weight of 248 kg. A dedicated electrical circuit of 110 to 120 V, 60 Hz, and 25 A is needed. The reader/incubator module can accommodate 120 specimens and controls but can be expanded to accommodate 240 specimens with controls.
Detection, identification, and quantitation is accomplished by the AMS urine identification card, which is a sealed, disposable, 20-well plate which is inoculated with the diluted specimen by means of the filling module. Nine of the wells contain selective media formulated to allow growth of only one organism (or closely related group of organisms) in a specific well. One other well contains nonspecific media and serves as the control well, allowing most organisms to grow in it. Five additional wells are responsible for quantitation.
The inoculated identification cards are incubated at 35 ± 1°C in the reader-incubator. Identification cards may be added at all times, except for a maximum of 6.5 min during each 15 (Table 2) showing an accuracy of 55% should be considered cautiously since it represents many specimens seeded with various organisms that the AMS is not capable of identifying. Some of these organisms would be rare isolates from urine specimens. Others would be considered as nonpathogenic or contaminants when isolated from urine specimnens.
Further discussion of organisms involved in this column is found in a later section.
The accuracy of true negative responses was determined to be 99%.
The average overall accuracy of organism identification was 95%. Polymicrobic specimen response. The results on 96 urine specimens containing two different organisms identifiable by the AMS were compared to our conventional methodology in Table 4 . Complete agreement was obtained in 90 specimens for a 94% correlation.
One discrepancy represented the failure of a P. aeruginosa to grow in the identification card.
Another discrepancy represented a difference in count, with the CML reporting E. coli and group D Enterococcus greater than 70,000 CFU/ml and the AMS reporting the same two organisms at a count of less than 70,000 CFU/ml. Three of the remaining discrepancies were due to one of the organisms present growing in and triggering one of the other wells. The remaining difference occurred in a specimen containing group D Enterococcus and KE group, with the AMS giving an unidentified organism response for unknown reasons.
Identification time. The AMS is so programmed that a status report for each culture may be requested and obtained at the end of 3 h of incubation. It would be of considerable aid if the time to positivity could be used as a presumptive indication as to whether the count is over 70,000 CFU/ml. The critical factor here is how many cultures containing organisms in quantities less than 70,000 CFU/rnl are also positive at the same time. Table 5 contains the percentage of each organism present in quantities greater than 70,000 CFU/ml identified by a certain hour of incubation. It can be seen that 81% of the specimens containing E. coli in quantities greater than 70,000 CFU/ml were positive by 6 h. At this same time interval, none of the 108 strains of E. coli present in quantities less than 70,000 CFU/ml had triggered a positive response. At 7 h, however, 3% of these strains were positive. KE group gave a 53% positive response at 7 h. None of the 18 strains of the KE group present in quantities less than 70,000 CFU/ml were positive at this time, but 6% became positive at 8 h. Proteus sp. identification is interesting in that 71% of the strains gave a positive response by 3 h of incubation. Twentyfive percent of the 32 strains of Proteus sp. present in quantities less than 70,000 CFU/ml were also positive after 3 h of incubation. P. aeruginosa results are similar to Proteus sp.
except that it takes 7 h of incubation to reach a 61% positivity level. During this same time period, 34% of the 32 strains of P. aeruginosa present in quantities less than 70,000 CFU/ml had become positive. Seventy-one percent of the group D Enterococcus strains were positive by Response comparison. As would be expected, the AMS and the CML did not always agree. Table 6 illustrates the discrepant results obtained. If one accepts the thesis that bacterial counts below 70,000 CFU/ml are not significant, then many of these differences would not present problems in interpretation. Additionally, since the presence of more than two organisms indicated a contaminated specimen, further differences are readily resolved. The above then leads one to the conclusion that only items 3 and 5c2 in Table 6 (Table 8) .
The number of daily, monthly, and yearly specimens needed to cover the cost of personnel time and expendable items, and the above two plus the instrument cost, are shown in Table 9 . To pay for the instrument-plus-specimen costs in 1 year would necessitate 30 specimens daily at our charge rate of $12.00 per urine specimen. Table 9 also shows that, with our workload of 21,000 urine specimens per year, we could pay for the instrument and the yearly specimen cost in 5.7 months. DISCUSSION The AMS represents a significant step in providing automation to clinical microbiology through the ability of this system to automatically analyze a patient urine specimen and provide quantitation and identification of the more common urinary tract pathogens. During the course of our evaluation we found the instrument to be very reliable and to require only around 5 min of routine maintenance daily. When problems did arise, the company responded rapidly.
Our studies in general agree with published studies on the AMS, confirming the fact that this system can contribute significantly in the examination of urine specimens in a CML (1-6).
A total time savings of 1.74 h per day would presumably be realized in our laboratory by using the AMS. This would have more significance if it involved one technologist or station. In our laboratory it would be divided among five to six technologists, thus somewhat reducing the value of its addition to the laboratory.
Quantitation obtainable by the AMS is quite accurate when the count is over 70,000 CFU/ml, except for yeast. The quantitative streaking-out of a blood agar plate with each specimen would alleviate the problem with yeast quantitation. We had 284 specimens with counts below 70,000 CFU/ml by the AMS method which correlated well with the CML method. Only seven specimens in this study were reported as having greater than 70,000 CFU/ml by the CML, whereas the AMS reported less than 70,000 CFU/ml. The reverse was true in only one specimen. The trend would seem to indicate fairly good correlation down to 10,000 CFU/ml. However, definite conclusions cannot be made due to the small number of specimens in this range. Until additional data are available, specimens in which counts less than 70,000 CFU/ml may be significant (catheterized, suprapubic aspirate, or cystoscopy specimens) should not be tested only by the AMS. The presence of more than one organism identifiable by the AMS obviously pro- CFU/ml Three or more organisms, >70,000 CFU per ml/<70,000 CFU per ml One to two organisms, >70,000 CFU/ml UIo a. >70,000 CFU/ml b. <70,000 CFU/ml One to two organisms a. >70,000 CFU/ml b. <70,000 CFU/ml Three or more organisms a. >70,000 CFU per ml/ <70,000 CFU/ml Same number More organisms than CML 1. Set up same day 2. Overnight delay Fewer organisms than CML One organism >70,000 CFU per ml/<70,000 CFU per ml >70,000 CFU/ml <70,000 CFU/ml Identification accuracy for all organisms identifiable by the AMS is good except for Citrobacter freundii. The negative or no growth correlation is also excellent.
The AMS system as it is marketed contains the capability of identifying C. freundii. Since this is an uncommon isolate from urine specimens in our laboratory, isolates from other types of specimens were utilized for seeding. We obtained a 60% identification accuracy and felt the media was at fault. However, results from other investigators indicate a high accuracy of identification (5). Consequently, we are not reporting any C. freundii results but are attempting to determine the reason for this discrepancy.
As it now stands, the AMS does not define the species of all the organisms it is capable of (3, 5) . We found this to be true also. One report (5) The presence of two AMS-identifiable organisms in a patient urine specimen produced a 94% correlation between the two methods. This would indicate that the AMS can correctly process urine specimens with up to two organisms present. In an additional experiment, 120 specimens containing various combinations of at least two organisms utilizing our control strains were set up. A high degree of correlation was obtained except for those combinations containing the E. coli strain and KE group strain, in which the latter was antagonistic to the former and inhibited the growth of the E. coli. Utilization of additional strains of E. coli and KE group failed to show other strains with this propensity. Again one has to remember that the presence of more than one organism produces problems in interpreting the significance of each isolate, since quantitation is based on all organisms present and not each one separately. Although the time when a well became positive may aid in making an interpretation of significance, it is not an absolute criterion, since there is variation in rate of growth among different strains. Additionally, any antagonistic or synergistic in vitro responses would affect the time to positivity.
Comparisons were made between the time when an organism triggered its homologous well and whether the final count was greater than or less than 70,000 CFU/ml in an attempt to determine the probable clinical significance of an isolate as reflected by the count. If the homologous well becomes positive within 6 to 7 h, in most cases the count will be over 70,000 CFU/ ml for E. coli, KE group, and group D Enterococcus. At 7 h, 92 and 61% of Proteus sp. and P. aeruginosa isolates, respectively, with counts greater than 70,000 CFU/ml will have exhibited a positive response whereas 47 and 34% of the same organisms, respectively, with counts less than 70,000 CFU/ml will also have triggered a positive response. Of more interest is the fact that, at 3 h of incubation, 71% of the Proteus sp. present in amounts greater than 70,000 CFU/ml will have given a positive response whereas 25% of the Proteus sp. present in amounts less than 70,000 CFU/ml will also have triggered a positive response. This obviously inserts a large degree of uncertainty in assigning significance to these organisms. Since yeast enumeration is only 50% accurate when the count is greater than 70,000 CFU/ml, this parameter cannot be used as a predictor of signifilcance. Due to the few patient urine specimens that contain Staphylococcus sp. and Serratia sp. in our hospital, comment concerning time to positivity significance based on clinical specimens is not warranted.
The different responses which occur when comparing the AMS and CML method could be cause for concern (Table 6 ). A determination of whether a urine specimen containing less than 70,000 CFU/ml is significant would depend on the method of collection, time of collection (early morning specimen versus midmorning specimen), possible presence of antimicrobial agents, and whether a previous specimen contained the same organism (follow-up culture after treatment). Table 6 shows that 407 specimens fall in this category when using the AMS response only. The fact that 111 cultures with counts over 70,000 CFU/ml containing multiple organisms were reported out by the AMS as one to two AMS-identifiable organisms or as unidentified organisms greater than 70,000 CFU/ml would seem to represent a risk of leading to unnecessary patient antimicrobial therapy. If the problem of presumably improperly collected specimens, which lead to the multiple organism response, cannot be resolved, then the best solution would appear to be the streaking-out of a blood and eosin methylene blue agar plate, incubation, and then comparison of the plates with the AMS response. It would be hoped that, through an educational campaign, improvement could be obtained in specimen collection. The accuracy of the AMS methodology for identification of more than two organisms in urine specimens will have to await additional data.
Although direct cost analysis indicates that the AMS method is more expensive than our conventional method (Table 7) , several other factors have to be considered in attempting to determine cost effectiveness. It is apparent (Table 8) that a significant amount of personnel time is saved on a daily basis by utilizing the AMS. Hopefully this time would be utilized to accomplish other tasks. It would also be hoped that the availability of a culture report in 13 h or less would lead to more rapid and correct treatment of patients with urinary tract infections. This would depend on the availability of a physician to institute treatment. It would also necessitate an educational campaign on the part of the laboratory so that the physician would be aware of the availability of urine culture reports in a much shorter period of time than was previously possible. This presumably would lead to a more rapid discharge from the hospital and consequently a more marked saving in patient charges. Setting up an antibiotic susceptibility on the positive cultures before or at the end of the 13-h incubation period would give a complete report within 24 h. This not only should benefit the patient from the treatment and cost standpoints but should enhance the microbiology laboratory status due to the markedly shortened turnaround time.
Utilizing direct costs only and not considering indirect costs, such as overhead, it is readily apparent from Table 9 that the cost of the AMS methodology can readily be amortized in our hospital. The ability to amortize within 5.7 months would seem to indicate that the charge per urine specimen should be significantly reduced. The cost effectiveness is going to vary from one laboratory to another depending upon methodology, personnel used, and number of specimens.
It would appear that the AMS could make a significant contribution to clinical microbiology by providing a urine culture result in 13 h or less. The upcoming availability of other AMS specimen procedures represents a giant step toward automation of microbiology and shortening of specimen turnaround time.
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